Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.
Dupont S, Massé A, James C, Teyssandier I, Lécluse Y, Larbret F, Ugo V, Saulnier P, Koscielny S, Le Couédic JP, Casadevall N, Vainchenker W, Delhommeau F. Dupont S, et al. Among authors: ugo v. Blood. 2007 Aug 1;110(3):1013-21. doi: 10.1182/blood-2006-10-054940. Epub 2007 Mar 27. Blood. 2007. PMID: 17389763 Free article.
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.
Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broët P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, Ifrah N, Witz F, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. Tamburini J, et al. Among authors: ugo v. Blood. 2007 Aug 1;110(3):1025-8. doi: 10.1182/blood-2006-12-061283. Epub 2007 Apr 10. Blood. 2007. PMID: 17426258 Free article. Clinical Trial.
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.
Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kröger N, Herrmann R, Prchal JT, Skoda RC, Hermouet S. Lippert E, et al. Among authors: ugo v. Haematologica. 2009 Jan;94(1):38-45. doi: 10.3324/haematol.13486. Epub 2008 Nov 10. Haematologica. 2009. PMID: 19001280 Free PMC article.
Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients.
Ugo V, Tondeur S, Menot ML, Bonnin N, Le Gac G, Tonetti C, Mansat-De Mas V, Lecucq L, Kiladjian JJ, Chomienne C, Dosquet C, Parquet N, Darnige L, Porneuf M, Escoffre-Barbe M, Giraudier S, Delabesse E, Cassinat B; French Intergroup of Myeloproliferative disorders. Ugo V, et al. PLoS One. 2010 Jan 26;5(1):e8893. doi: 10.1371/journal.pone.0008893. PLoS One. 2010. PMID: 20126644 Free PMC article.
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.
Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O. Cabagnols X, et al. Among authors: ugo v. Leukemia. 2015 Jan;29(1):249-52. doi: 10.1038/leu.2014.270. Epub 2014 Sep 12. Leukemia. 2015. PMID: 25212275 No abstract available.
90 results